Targeted estrogen delivery reverses the metabolic syndrome-Reference-Cited by-同舟云学术

Targeted estrogen delivery reverses the metabolic syndrome

Published:2012-11-11 Issue:12 Volume:18 Page:1847-1856
ISSN:1078-8956
Container-title:Nature Medicine
language:en
Short-container-title:Nat Med

Author:

Finan Brian,Yang Bin,Ottaway Nickki,Stemmer Kerstin,Müller Timo D,Yi Chun-Xia,Habegger Kirk,Schriever Sonja C,García-Cáceres Cristina,Kabra Dhiraj G,Hembree Jazzminn,Holland Jenna,Raver Christine,Seeley Randy J,Hans Wolfgang,Irmler Martin,Beckers Johannes,de Angelis Martin Hrabě,Tiano Joseph P,Mauvais-Jarvis Franck,Perez-Tilve Diego,Pfluger Paul,Zhang Lianshan,Gelfanov Vasily,DiMarchi Richard D,Tschöp Matthias H

Publisher

Springer Science and Business Media LLC

Subject

General Biochemistry, Genetics and Molecular Biology,General Medicine

Link

http://www.nature.com/articles/nm.3009.pdf

Reference40 articles.

1. Grundy, S.M. Drug therapy of the metabolic syndrome: minimizing the emerging crisis in polypharmacy. Nat. Rev. Drug Discov. 5, 295–309 (2006).

2. Roth, J.D. et al. Leptin responsiveness restored by amylin agonism in diet-induced obesity: evidence from nonclinical and clinical studies. Proc. Natl. Acad. Sci. USA 105, 7257–7262 (2008).

3. Müller, T.D. et al. Restoration of leptin responsiveness in diet-induced obese mice using an optimized leptin analog in combination with exendin-4 or FGF21. J. Pept. Sci. 18, 383–393 (2012).

4. Drucker, D.J. The biology of incretin hormones. Cell Metab. 3, 153–165 (2006).

5. Barrera, J.G., Sandoval, D.A., D'Alessio, D.A. & Seeley, R.J. GLP-1 and energy balance: an integrated model of short-term and long-term control. Nature reviews. Endocrinology 7, 507–516 (2011).

Cited by 244 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Protein restriction associated with high fat induces metabolic dysregulation without obesity in juvenile mice;2024-07-23

2. Combination therapy enhances efficacy and overcomes toxicity of metal‐based anti‐diabetic agent;British Journal of Pharmacology;2024-07-04

3. GLP-1-directed NMDA receptor antagonism for obesity treatment;Nature;2024-05-15

4. Oral peptide therapeutics for diabetes treatment: State-of-the-art and future perspectives;Acta Pharmaceutica Sinica B;2024-05

5. The emerging role of glucagon-like peptide 1 in binge eating;Journal of Endocrinology;2024-04-17